Real-World Study of IL-23 Inhibitors in Active Crohn's Disease Launched
A real-world observational study has been initiated to assess the effectiveness and safety of IL-23 inhibitors in adults with active Crohn's disease.
Asset / Drug
Drug and asset intelligence for Real-World with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
IL-23 Inhibitors
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.